S 81694 Plus Paclitaxel in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2020-06-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety profile, the maximum tolerated dose
(MTD) and the associated dose-limiting toxicities (DLTs) of S 81694 in combination with
paclitaxel in metastatic breast cancer (mBC) patients, and to investigate the antitumour
activity of the combination in metastatic triple negative breast cancer (mTNBC) patients.